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From the Editor’s Desk
HEALTH POLICIES:
THE ART OF THE POSSIBLE
In the recent federal election, politicians 
criss-crossed the nation promoting their 
policies, and health was foremost in their 
bidding war. Labor’s Medicare Gold made a 
grab for the grey vote: free medical care and 
no waiting lists for citizens aged over 75! 
Labor also promoted itself as the true 
guardian of Medicare, promising higher 
rebates and other incentives for general 
practitioners to shore up bulk-billing and 
also offering incentives for after-hours GP 
clinics.
Prior to the campaign, the Liberals 
championed Medicare, pushing their 
safety-net to cover 80% of out-of-pocket 
medical expenses above $500 per year. 
They increased GP rebates, whether 
doctors bulk-billed or not, and also pushed 
for after-hours GP services. 
Interestingly, both parties pledged to 
retain the private health insurance rebate.
Despite the constant cries by state 
premiers that their hospitals were on the 
verge of collapse, campaigning politicians 
invaded the wards for photo opportunities 
and policy-bites destined for prime-time 
television. All the while, the Greek chorus 
of political commentators, professional 
associations and self-interest groups 
chanted with delight, dismay or discontent 
at each policy release.
What are we to make of all this?
In promoting a health and welfare 
system free from cost constraints, both 
parties effectively ignored the twin 
pressures of surging demand for health 
services and spiralling costs. Furthermore, 
the waste inherent in the federal/state 
health divide was conveniently cast aside.
Playwright and first President of the 
Czech Republic, Václav Havel, once 
observed that politics is not only the art of 
the possible but also of the impossible. The 
former is the easy road. The latter is more 
challenging — it requires creative reform 
and fearless advocates.
Will we now have three years of the 
possible or the impossible?
Martin B Van Der Weyden
521
LETTERS
  The Medical Journal of Aus-
tralia ISSN: 0025-729X 15
November 2004 181 10 578-
580
©The Medical Journal of Aus-
tralia 2004 www.mja.com.au
Letters
A2 milk is allergenic
William B Smith,* Deryn Thompson,† 
Margaret Kummerow,‡ 
Patrick Quinn,‡ Michael S Gold‡
* Physician, † Registered Nurse, ‡ Paediatrician, 
AllergySA, East Adelaide Medical Centre, 
Suite G1, 50 Hutt Street, Adelaide, SA 5000. 
allergysa@internode.on.net
TO THE EDITOR: Recent media reports
have claimed numerous health benefits for A2
milk1,2 (eg, “new wave milk”, “wonder milk”).
It is becoming more widely available, particu-
larly in health food shops, and is advertised on
Queensland t levision. We believe it is impor-
tant to offer clear information about this prod-
uct and cows’ milk allergy.
A2  m i lk  i s  produce d  by  co ws
homozygous for the A2 polymorphic variant
(his→pro) at amino acid 67 of the -casein
gene. A difference in degradation patterns of
the A1 and A2 variants is purported to lead
to differences in immunological or pharma-
cological effects,3-5 which we will not com-
ment on here. Regarding cow’s milk allergy,
β-casein is one of at least seven proteins in
cows’ milk with allergenic significance (α-,
β- and κ-casein, α- and β-lactoglobulin,
lactoferrin and transferrin). One would not
expect a single amino-acid difference in one
protein to have a significant effect on milk
allergenicity.
We have found in discussion with parents
of milk-allergic children, as well as from
inquiries from the community to AllergySA,
that there is a perception that A2 milk may be
less allergenic than “normal” milk (which
contains A1 and A2 -casein). Although most
proponents of A2 milk have made no explicit
claims about allergenicity — and indeed
some have cautioned against the use of A2 in
milk-allergic individuals — there have been
media reports that may have led to this
perception.6 However, these reports are mis-
leading. For example, it is quite likely that
children with a previous history of cow’s milk
allergy who have been found to tolerate A2
milk have in fact “grown out” of the allergy,
which is the usual natural history. Others may
never have had true milk allergy.
We obtained a sample of pure A2 milk from
A2 Dairy Marketers (Acacia Ridge, QLD) and
used it for skin-prick testing of 11 consecutive
milk-allergic children (Box). The tests com-
pared A2 milk with “normal” (A1/A2) milk
and cow’s milk protein extract. The mean
diameter of the wheal raised by normal milk
was not significantly different to that raised by
A2 milk (8.2mm for normal milk v 10.7 mm
for A2 milk; P =0.09, paired t test). No patient
had a negative reaction to A2 milk when the
reaction to normal milk was positive.
We did not perform an oral challenge
with A2 milk in these children, as many had
experienced severe allergic reactions, and
the predictive value of a positive skin-prick
test in the presence of a clear recent history
of clinical allergy is high.
We therefore caution that A2 milk should
not be used by those with IgE-mediated
cow’s milk allergy, particularly those who
have had recent severe reactions to milk.
1 Today Tonight [television broadcast]. Channel 7.
Episodes broadcast on 31 Mar 2003, 1 Apr 2003, 21
Jul 2003, 15 Sep 2003, 9 Feb 2004. Transcripts
available at: http://seven.com.au/todaytonight
(search for “A2”) (accessed Jul 2004).
2 Autism, milk link research hidden. The Australian
2002; Nov 13: 1.
3 McLachlan CN. beta-casein A1, ischaemic heart
disease mortality, and other illnesses. Med Hypoth-
eses 2001; 56: 262–272.
4 Laugesen M, Elliott R. Ischaemic heart disease,
Type 1 diabetes, and cow milk A1 beta-casein. N Z
Med J 2003; 116: U295.
5 A2 Corporation. About A2 milk. Available at:
www.a2corporation.com (accessed Aug 2004).
6 Collins S. Milking the health advantages of A2. The
New Zealand Herald 2003; 7 Apr. Available at:
www.nzh era ld .co .nz /s to rydisp la y.cfm?s to -
ryID=3351045 (accessed Aug 2004).  ❏
Prescribing of amino acid 
infant formula
Andrew S Kemp
Professor of Paediatric Allergy, The Children's
Hospitalat Westmead, Locked Bag 4001, Westmead, 
NSW 2145. andrewk5@chw.edu.au
TO THE EDITOR: There appear to be regional
differences in the prescribing of amino acid   
infant formula in Australia. This is possibly
due to differing practices in use of this formula
as a first-line treatment for cow's milk al1-
ergy or as a strategy for preventing allergy.
This has financial implications, as the cost to
the PBS of amino acid formula is $371 per pre-
prescription, compared with $106 for hydrolysed 
protein formula.1

In infants at high risk of allergic disease who 
are unable to be completely breastfed, there 
is evidence that prolonged feeding with a formula 
based on hydrolysed cow’s milk protein rather 
than conventional cow’s milk formula reduces infant 
and childhood allergy.2,3 There is no clear evid- 
ence that amino acid formula should be substituted 
for extensively hydrolysed protein formula as a primary 
preventive strategy.3 
The current PBS indication fed
hydrolysed protein formula is treatment of intolerance
to both cow’s milk and soy protein, but not
primary allergy prevention. Similarly, cur-
rent PBS guidelines restrict the use of amino
acid formulas to proven intolerance to cow’s
milk, soy protein and protein hydrolysate.
Among children who are allergic to cow’s
milk, 10% or less are also sensitive to pro-
tein hydrolysate formula.4 Thus, if current
guidelines were followed, one might expect
nine times the use of hydrolysed protein
formula compared with amino acid formula.
I obtained statistics on PBS items supplied
for the period January 2003 to January 2004
from the Health Insurance Commission
(www.hic.gov.au/statistics/dyn_pbs/forms/
pbs_tab1.shtml) for hydrolysed protein for-
mula (item numbers 2676W and 8259Q)
and synthetic amino acid formula (item
numbers 3066J, 8443J, 8574G and 8575H).
These showed that 8374 hydrolysed protein
formula items were supplied, half the
number of amino acid formula items
(16 886).
Numbers of amino acid formula items
supplied per 1000 children aged 4 years and
younger were calculated using population
statistics from the Australian Bureau of Sta-
tistics census figures 2001. These are com-
pared in the Box with numbers of paediatric
physicians per 1000 children (obtained
from the Royal Australasian College of Phy-
sicians 2004) and paediatric allergists
(derived from the Australasian Society of













1 12 10 8 4.5
2 11.5 12 11 5.5
3 4 8 6 15
4 8 11 10.5 3
5 12 8 6 9
6 3 5 2 9
7 7 15 7 10
8 7 7.5 5 7.5
9 6 7.5 4 3.5
10 13 25 4.5 3
11 7 9 3 5
Mean 8.2 10.7 6.1 6.8
* As wheals produced are not necessarily circular, it 
is standard to report diameter as the mean of two 
measurements taken perpendicular to each other. 
Results for all negative controls were 0 mm.
† Normal and A2 milk were stored frozen, and 
aliquots thawed for testing. They do not produce 
wheal reactions in non-allergic individuals.
‡ Cows’ milk extract is manufactured for skin-prick 
allergy testing by Hollister-Stier, Wash, USA, and 
purchased from Richard Thomson, Sydney, NSW. 574 MJA • Volume 181 Number 10 • 15 November 2004
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ship handbook 2003).
Prescribing practice varied markedly
between states and territories. The Austral-
ian Capital Territory, New South Wales and
Victoria had six to seven times more amino
acid formula items per 1000 children than
Western Australia. This did not appear
related to numbers of paediatricians or pae-
diatric allergists, as Western Australia had a
similar number of paediatricians and more
paediatric allergists per 1000 children than
NSW and Victoria.
The differences found were unlikely to be
related to variation in numbers of adult
immunology/allergy specialists, who are
unlikely to treat many infants aged under 2
years. Nor were they likely to be due to
differing prevalence of combined milk, soy
and protein hydrolysate intolerance, as the
prevalence of allergic disease does not differ
markedly between Australian states. For
example, the prevalence of atopic eczema at
age 6 years in four cities (Adelaide, Mel-
bourne, Sydney and Perth) was very similar,
ranging from 10.1% to 11.4%.5 It seems
unlikely that 80% of cases of combined
intolerance are being missed in Western
Australia. The estimated cost to the PBS for
amino acid formula for 2003–2004 of
$7 107 627 was 10 times that of hydrolysed
formula ($757 570).
1 Australian Government Department of Health and
Ageing. Schedule of pharmaceutical benefits for
approved pharmacists and medical practitioners.
Effective from 1 August 2004. Available at:
www1.health.gov.au/pbs/ (accessed Oct 2004).
2 Osborn D, Sinn J. Formulas containing hydrolysed
protein for prevention of allergy and food intoler-
ance in infants. Cochrane Database Syst Rev 2003;
4: CD003664.
3 Host A, Halken S. Hypoallergenic formulas — when,
to whom and how long: after more than 15 years we
know the right indication! Allergy 2004; 59 Suppl 78:
45-52.
4 Giampietro PG, Kjellman NI, Oldaeus G, et al. Hypoal-
lergenicity of an extensively hydrolyzed whey formula.
Pediatr Allergy Immunol 2001; 12: 83-86.
5 Williams H, Robertson C, Stewart A, et al. World-
wide variations in the prevalence of symptoms of
atopic eczema in the International Study of Asthma
and Allergies in Childhood. J Allergy Clin Immunol
1999; 103: 125-138 ❏
Rectal perforation from 
colonic irrigation 
administered by alternative 
practitioners
Doug V Handley,* Nick A Rieger,† 
David J Rodda†
* Surgeon, Repatriation General Hospital, Daw Park, 
SA. Greenhill Chambers, 13 Greenhill Road, Wayville 
SA 5034. † Surgeon, University Department of 
Surgery, Queen Elizabeth Hospital, Woodville, SA. 
handley@impala.net.au
TO THE EDITOR: Colonic irrigation is the
introduction of a large volume of fluid into
the colon via the rectum. This volume may
be up to 50 litres, run in and out by means
of a rectal tube, in an effort to empty the
bowel. This treatment is often administered
by a practitioner of complementary or alter-
native medicine, without medical advice.
The fluid may be driven by gravitational or
mechanical force.1 Recognised risks from
colonic irrigation are electrolyte imbalance,
bowel perforation and communicable dis-
eases such as amoebiasis.2
Colonic irrigation is different from a
standard enema given to relieve constipation
or to treat a primary bowel disease. An
enema involves a small amount of fluid and
is usually authorised by a medical practi-
tioner and administered by a trained nurse,
attendant or is self-administered. Perfora-
tion of the rectum has rarely been reported.3
We document three cases of perforation of
the rectum from colonic irrigation, treated by
different surgeons at different institutions
(Box). All have required surgical intervention.
Each patient underwent colonic irrigation to
relieve chronic constipation, to “cleanse” or
“clear out stale faeces”. None had primary
colonic or rectal pathology. None of the three
patients were warned about the complication
of perforation. Importantly, one patient ini-
tially denied the use of colonic irrigation,
even with direct enquiry (Case 1), presuma-
bly because of embarrassment. This has the
potential to delay the diagnosis or lead to
inappropriate treatment.
Perforation may occur in the rectum by
direct injury from the irrigation device (Case
1), or after the irrigation has commenced
(Cases 2 and 3), and may be caused by the
generation of a high pressure within the
lumen of the bowel.
Rectal perforation from colonic irrigation
may be diagnosed from the history, plain
abdominal x-rays or a computed tomogra-
phy scan with or without meglumine diatri-
zoate enema. A high degree of suspicion by
the attending physician will prompt the
diagnosis. Intensive medical therapy with
appropriate antibiotics and surgery is neces-
sary. Plain abdominal x-ray did not show an
abnormality at 12 hours in the one case
where x-ray was taken.
We feel that colonic irrigation is of dubi-
ous benefit, especially when delivered to
remove so-called “toxic waste” when bowel
Amino acid formula prescription rates, January 2003 to January 2004, compared 
with numbers of paediatric physicians and allergists per 1000 children aged 
4 years or younger
Amino acid formula 





Australian Capital Territory 22.3 0.79 0
New South Wales 18.8 1.02 0.033
Victoria 17.8 1.00 0.030
Tasmania 12.3 0.53 0.033
South Australia 9.3 1.01 0.067
Northern Territory 9.1 0.92 0
Queensland 5.9 0.72 0.008
Western Australia 3.3 0.99 0.049
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function is satisfactory. There is potential
for serious harm. The apparent failure of
the operators to warn patients about a risk
of any serious complication, the failure to
diagnose the possible perforation at the
time of injury, and the failure to provide
any subsequent follow-up, which might
have led to an earlier diagnosis of any
complication, probably indicates subopti-
mal practice. Cases 2 and 3 occurred at the
same clinic within a few weeks of each
other, suggesting a possible systems failure
of the irrigation device.
Primary healthcare practitioners need to
be aware of the dangers of this treatment.
Colonic irrigation should be urgently and
formally assessed from an evidence-based,
risk–benefit perspective.
1 Colonic irrigation and the theory of autointoxica-
tion: a triumph of ignorance over science [editorial].
J Clin Gastroenterol 1997; 24: 196-198.
2 National Health and Medical Research Council
Medicine Advisory Committee. Colonic irrigation.
Report of the Session (NHMRC) 1982 October Can-
berra. Canberra: NHMRC, 1982. (Indexed in Austral-
asian Medical Index Jan 2004.)
3 Parun H, Butnarug G, Neufeld D, et al. Enema
induced perforation of the rectum in chronically
constipated patients. Dis Colon Rectum 1999; 42:
1609-1612. ❏
Case descriptions for three women who had rectal perforation after undergoing colonic irrigation
Case Age (years) Timing of symptoms Clinical features Investigations Management
1 59 Pain immediately on insertion 
of enema tube. No irrigation. 
Attended emergency 
department 24 hours after the 
tube insertion. 
Lower abdominal and 
deep pelvic pain. 
Sepsis.
Abdominal computed 
tomography scan showing 
perirectal oedema and 
extrarectal gas.
Intravenous antibiotics and transrectal 
drainage of perirectal abscess.
2 51 Pain started during irrigation. 
Attended emergency 
department 4 days after 
irrigation.
Lower abdominal pain. 
Sepsis.
Abdominal computed 
tomography scan showing 
gas and fluid in the 
perirectal fat and 
retroperitoneum.
Intravenous antibiotics and initial 
transrectal drainage of perirectal 
abscess. Recurrent abscess formation 
required laparotomy and rectal 
resection with stoma formation.
3 56 Pain started during irrigation. 
Attended emergency 
department the same day, but 
was discharged. Re-presented
7 days later.
Lower abdominal and 
deep pelvic pain. 
Constipation and urine 
retention leading to 
urinary infection. Sepsis.
Abdominal computed 
tomography scan showing 
pelvic abscess posterior to 
the rectum.
Emergency laparotomy, sigmoid loop 
colostomy and drainage of abscess. 
Residual abscess drained transrectally 
2 weeks after initial surgery.576 M JA • Volume 181 Number 10 • 15 November 2004
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Critical shortage of injectable 
thiamine in Australia
Simon Spedding,* Matt D Gaughwin†
* Advanced Trainee, Australasian Faculty of Public 
Health Medicine; † Director, Drug and Alcohol 
Resource Unit, Drug and Alcohol Services Council of 
South Australia, Royal Adelaide Hospital, 
Adelaide, SA.
TO THE EDITOR: There is no substitute
for injectable thiamine in the treatment
and prevention of Wernicke’s encephalo-
pathy, for which the oral form of thiamine
is considered inadequate.1 If the condition
is not treated promptly with parenteral
thiamine, permanent brain damage can
occur.
A shortage of injectable thiamine noted in
a South Australian hospital led us to enquire
into the extent of the problem in Australia.
In the first week of July 2004, we undertook
an Australia-wide survey of major teaching
hospital pharmacies. Sixteen hospitals were
contacted by phone, and 15 chief hospital
pharmacists provided information about
thiamine stock, normal thiamine usage over
a 6-month period, shortages of other drugs,
and reasons for shortages. Data on thiamine
are shown in the Box.
Most hospitals (11/15) were unable to
provide injectable thiamine for periods
ranging from a few weeks to 5 months.
Rationing reduced the use of injectable thia-
mine in 13/15 hospitals. There was a total
shortfall of 2000 ampoules per month for
the 13 hospitals. Given an average of six
ampoules used per admission, we estimate
that 330 patients a month were untreated or
inadequately treated.
Half the hospitals surveyed obtained
some ampoules either directly from suppli-
ers or through the Special Access Scheme
(SAS) protocol of the Therapeutic Goods
Administration (TGA). This protocol is
time-consuming and cumbersome, while
the non-SAS system is expensive (10 times
the usual price per ampoule). Pharmacists
reported having many other drugs (40–60)
on back order.
The pharmacists stated that drug short-
ages were caused by scarcity of raw materi-
als and TGA restrictions. However, the
current shortage of thiamine in Australia
was foreseeable in 2003, when the main
Stocks and usage of injectable 
thiamine in 15 Australian hospitals, 
as at 3 July 2004*





1 0 0 0 16
2 0 0 0 50
3 0 0 0 50
4 0 0 0 65
5 0 12 0 20
6 0 10 0 35
7 0 25 0 20
8 0 200 0 130
9 0 120 0 1200
10 0 25 25 70
11 0 10 10 150
12 1 35 40 120
13 5 160 17 180
14 25 86 100 100
15 30 90 30 30
* The table compares the level of stock at its 
lowest during the shortage with the level at July 
2004, along with estimates of use at July 2004 and 
before the shortage.MJA • Volume 181 Number 10 • 15 November 20
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The TGA did not alert pharmacists or doc-
tors to the potential shortage in writing, nor
provide comprehensive help to prevent or
alleviate the shortages.
The public health response to shortages of
essential medicines should include surveil-
lance and a systematic analysis of the causes.
Better communication between pharmacists,
clinicians and government authorities, and
the formation of contingency plans and
guidelines, are needed. It was only through
informal networking and the quick thinking
of hospital pharmacists that a crisis was
averted in Australia.
It is unconscionable that an inexpensive
essential medicine is not available to those
Australians who may need it. In this respect,
our public health system has failed. Because
injectable thiamine has been unavailable or
rationed, an increase in the incidence of
alcohol-related brain damage may have
occurred. Australian health ministers should
act immediately to prevent critical shortages
of essential medication, which could be
tragic and costly.
1 Thomson A, Cook C, Touquet R, Henry J. The Royal
College of Physicians report on alcohol: guidelines
for managing Wernicke’s encephalopathy in the
accident and emergency department. Alcohol
Alcohol 2002; 37: 513-521. ❏
Pertussis vaccination for 
new parents?
Brad J McCall,* Rod P Davison,† 
Michael D Nissen,‡ Clare B Nourse§
* Public Health Physician, Brisbane Southside Public 
Health Unit, PO Box 333, Archerfield, QLD 4108; 
† Public Health Physician, Brisbane Northside Public 
Health Unit, ‡ Director of Infectious Diseases and Clin-
ical Microbiologist, Royal Children’s Hospital and 
Queensland Health Pathology and Scientific Services, 
§ Paediatric Infectious Disease Physician, Mater Health 
Services, and Associate Professor, University of 
Queensland, Brisbane, QLD. 
Brad_mccall@health.qld.gov.au
TO THE EDITOR: Pertussis (whooping
cough) is a readily transmissible respiratory
infection that may cause severe respiratory
illness. The burden of severe pertussis
affects infants, often resulting in hospitalisa-
tion (especially those aged under 6 months)
and death (1 in every 200 patients aged
under 6 months).1,2
In Australia, there were nine deaths from
pertussis between 1993 and 1997, predomi-
nantly in young infants, and a further five
young infant deaths during the 2001–2002
epidemic.3,4 Epidemics occur every 3 to 4
years.2 Pertussis cases and hospitalisations
in children aged under 6 months continue
to occur in south-east Queensland, with 19
notifications since January 2003.
There has been a shift in the epidemiology
of pertussis in Australia and the United
States, from a disease of young children to a
disease of adolescents and adults of child-
bearing age.1,5 In Australia, there has been a
preponderance of pertussis notifications in
adult females.5
Pertussis vaccine is already provided free
to children at ages 2, 4 and 6 months, 4
years and 15 years, as part of the National
Immunisation Program.2 However, young
infants remain incompletely protected by
vaccination, as the third, completion dose of
the primary course of pertussis vaccination
is not given until 6 months of age. A
national study of hospitalised infant pertus-
sis cases in 2001 indicated that parents were
the presumptive source of pertussis infec-
tion for their children in more than 50% of
cases.6 This has led the National Health and
Medical Research Council to recommend
that both parents should receive a (once-
only) adult booster dose of pertussis vac-
cine, either when planning pregnancy or as
soon as possible after delivery of an infant.2
The cost of the vaccine is about $30.
As yet there is no suggestion that funding
will be made available to provide this vac-
cine to all new parents as part of the
National Immunisation Program. However,
the amount is not a high price to pay for the
protection of a new baby and its parents,
particularly now that new parents will
receive additional financial support from the
federal government. The potential exists to
promote opportunistic maternity-ward-
based administration of this vaccine to post-
partum mothers and their partners. We
encourage all medical practitioners, espe-
cially obstetricians and paediatricians, to
discuss this important issue with parents.
1 Guris D, Strebel PM, Bardenheier B, et al. Changing
epidemiology of pertussis in the United States:
increasing reported incidence among adolescents
and adults, 1990-1996. Clin Infect Dis 1999; 28:
1230-1237.
2 National Health and Medical Research Council. The
Australian immunisation handbook. 8th ed. Can-
berra: Commonwealth of Australia, 2003.
3 McIntyre P, Amin J, Gidding H, et al. Vaccine pre-
ventable diseases and vaccination coverage in Aus-
tralia, 1993-1998. Commun Dis Intell 2000 Suppl: 24.
4 Australian Institute of Health and Welfare. The
AIHW national mortality database. Canberra: Aus-
tralian Government, 2004.
5 Communicable Diseases Surveillance Highlights.
Vaccine preventable diseases. Commun Dis Intell
2000; 24: 11.
6 Elliot E, McIntyre P, Ridley G, et al. National study of
infants hospitalized with pertussis in the acellular
vaccine era. Pediatr Infect Dis J 2004; 23: 246-252. ❏
To exercise or not to exercise 
in chronic fatigue syndrome?
Garry C Scroop,* Richard B Burnet†
* Visiting Associate Professor in Exercise Physiology, 
Department of Thoracic Medicine; † Endocrinologist, 
Royal Adelaide Hospital, SA 5000 
gscroop@mail.rah.sa.gov.au
TO THE EDITOR: A recent editorial1 and
article2 continue to promulgate and link the
unproven concepts that patients with
chronic fatigue syndrome (CFS) are “decon-
ditioned” and exercise is beneficial in treat-
ment. The cited study by Fulcher and
White3 is open to opposite conclusions,
depending on their use of the outcome
descriptor “better”. If the term is restricted
to “much better” and “very much better”,
then, as cited by Lloyd,1 16 of 29 people
with CFS rated themselves as “better” after a
graded exercise program, compared with
only 8 of 30 in the control group who
completed a flexibility treatment regimen.
However, if the “better” descriptor combines
“a little better”, “much better” and “very
much better”, which is the interpretation
used by Wallman et al,2 then the scores for
the exercise versus flexibility groups are not
different, being 27 of 29 and 26 of 30,
respectively, agreeing with the conclusion of
Wallman et al.2
Whichever interpretation is applied, any
beneficial effect of the graded exercise pro-
gram in people with CFS in these studies
must be independent of any training effect
or change in level of “conditioning”, as this
was reported in one study,2 but not in the
other.3
A fundamental flaw with most exercise
studies in CFS is the use of submaximal or
symptom-limited tests, which provide noto-
riously misleading data when compared
with maximal exercise testing procedures.4,5
Wallman et al2 correctly identify maximal
oxygen consumption as the “gold standard”
measure of exercise capacity, yet such meas-
urements were not made in the three articles
they cited. When such procedures are
applied, the exercise capacity of people with
CFS is not significantly different from either
measured or age-predicted values for
healthy sedentary people.6 Wallman et al2
suggested that maximal testing procedures
could favour the recruitment of “more
robust or healthier” patients and provide
misleading information. In the first place
this is denied by the study of Sargent et al,6
in which the illness status reported by
patients who completed the maximal tests
was similar to that in previous CFS studies.
In the second place, the maximal test proto-578 MJA • Volume 181 Number 10 • 15 November 2004
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designed to exclude any influence of fatigue
on the metabolic measurements. This is
confirmed by the results from the study
cited,6 in which the metabolic measure-
ments met the published criteria of a maxi-
mal test.4,5
In summary, patients with CFS are not
“deconditioned”. Neither their muscle
strength nor their exercise capacity is differ-
ent from that of other sedentary members of
the community (> 70%). We remain una-
ware of any incontrovertible evidence that
the various “exercise training” programs
suggested in previous articles improve either
the physiological or clinical status of people
with CFS.
1 Lloyd AR. To exercise or not to exercise in chronic
fatigue syndrome? No longer a question [editorial].
Med J Aust 2004; 180: 437-438. 
2 Wallman KE, Morton AR, Goodman C, et al. Ran-
domised controlled trial of graded exercise in
chronic fatigue syndrome. Med J Aust 2004; 180:
444-448. 
3 Fulcher KY, White PD. Randomised controlled trial
of graded exercise in patients with the chronic
fatigue syndrome. BMJ 1997; 314: 1647-1652.
4 Sargent C, Scroop GC. Defining exercise capacity,
exercise performance and a sedentary lifestyle.
Med Sci Sports Exerc 2002; 34: 1692-1693.
5 Sargent C, Scroop GC. VO2peak versus VO2max? An
important distinction. Med Sci Sports Exerc 2002;
34: 1215-1216.
6 Sargent C, Scroop GC, Nemeth PM, et al. Maximal
oxygen uptake and lactate metabolism are normal
in chronic fatigue syndrome. Med Sci Sports Exerc
2002; 34: 51-56. ❏
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TO THE EDITOR: The claim in Lloyd’s
editorial1 that “the criteria for diagnosis are
well accepted internationally” ignores the
recent publication of the Canadian consen-
sus guidelines for the diagnosis and man-
agement of myalgic encephalomyelitis/
chronic fatigue syndrome,2 which were
sponsored by Health Canada and written
by an international group of well published
researchers. The Canadian definition of
chronic fatigue syndrome (CFS) requires
the concurrent presence for six months of
fatigue, post-exertional fatigue, sleep dys-
function, pain (including headaches) and
neurological/cognitive manifestations, as
well as at least one symptom from two of
autonomic, neuroendocrine and immune
manifestation categories (pp 12–13). These
requirements add clinical specificity to the
Fukuda criteria and exclude subjects who
may have chronic fatigue for other reasons,
such as psychiatric disorder without multi-
ple physical symptoms.
Lloyd refers to the “recent refinements to
improve reliability” in the revision of the
research case definition by Reeves et al.3
The SPHERE screening instrument recom-
mended by that article was designed for
psychiatric screening in primary care. It
arbitrarily classifies people with multiple
physical symptoms, often severe in degree
and associated with major disability, as
having somatisation disorder. This is akin
to subclassifying people with severe multi-
ple sclerosis as having somatoform disorder
and those with fewer and less severe symp-
toms as the “core” multiple sclerosis group,
a finding which is not supported by the
evidence.
Conclusions from the article by Wallman
et al4 cannot be generalised to the severely
ill. Recruitment was from “notices placed in
medical surgeries and by advertisements in
local newspapers”. Patients with severe
CFS, who can barely venture outside their
homes and are often too ill to read, would
be unlikely to participate. Loblay, Chair of
the Royal Australasian College of Physi-
cians Working Group for CFS Clinical
Practice Guidelines, urges caution about
generalising from exercise studies, which
never include people with severe CFS: “All
these studies involve people willing and
able to participate. The people who find it
makes them feel lousy drop out.”5
Lloyd asserts exercise is no longer a ques-
tion (“. . . graded physical exercise should
become a cornerstone of the management
approach for patients with CFS”). To pro-
mote such a strong, unqualified message to
busy general practitioners who may be unfa-
miliar with the range of severity in CFS risks
serious harm to patients.
1 Lloyd AR. To exercise or not to exercise in chronic
fatigue syndrome? No longer a question [editorial].
Med J Aust 2004; 180: 437-438. 
2 Carruthers BM, Jain AK, De Meirleir K, et al. Myalgic
encephalomyelitis/chronic fatigue syndrome: clini-
cal working case definition, diagnostic and treat-
ment protocols. J Chronic Fatigue Syndr 2003; 11:
7-116. Available at: www.mefmaction.net/docu-
ments/journal.pdf (accessed Sep 2004).
3 Reeves WC, Lloyd A, Vernon SD, for the Interna-
tional Chronic Fatigue Syndrome Study Group.
Identification of the ambiguities in the 1994 chronic
fatigue syndrome research case definition and rec-
ommendations for resolution. BMC Health Serv Res
2003; 3: 25.
4 Wallman KE, Morton AR, Goodman C, et al. Ran-
domised controlled trial of graded exercise in
chronic fatigue syndrome. Med J Aust 2004; 180:
444-448. 
5 Maegraith D. Pros and cons of exercise in fighting
CFS. The Weekend Australian 2004; Jul 3-4: C32. ❏
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IN REPLY: Scroop and Burnet correctly
identify the vagaries of the necessarily sub-
jective measurement of outcomes in inter-
vention studies of chronic fatigue syndrome
(CFS). Given that muscle strength, endur-
ance and recovery are essentially normal in
patients with CFS,1 rather than become too
focused on the best approach to measure-
ment of exercise capacity the key issue is
whether patients benefit in terms of self-
reported symptom severity or functional
status.
The weight of evidence indicates that
graded physical exercise does provide such
benefits. Whether this occurs via improve-
ments in aerobic fitness or via the well-
recognised psychological and social bene-
fits of exercise is something of a side-issue.
Stein and Hunter draw attention to the
recently published Canadian consensus
guidelines for the diagnosis and manage-
ment of myalgic encephalomyelitis/CFS.
Although this document may provide a
welcome recognition for Canadian patients
with the disorder, unlike the Australian
guidelines,2 it is devoid of an evidence base
for the recommendations. Sadly, rather
than “add[ing] clinical specificity”, it is also
highly likely that the modified diagnostic
criteria fall into the trap of preferentially
identifying patients with somatisation dis-
order,3 as such individuals often report
large numbers of unexplained symptoms,
and hence the addition of 20 or more
symptoms to the diagnostic criteria may
well bias towards inclusion of such
patients.
Stein and Hunter are incorrect in the
assertion that SPHERE was designed for
psychiatric screening in primary care, as
the instrument arose out of our studies in
CFS specifically seeking to identify clini-
cally significant fatigue states.4
I support the recommendation about
caution in generalising from existing pub-
lished data regarding graded exercise to
patients who are severely ill, as such
patients are indeed likely to be under-
represented in published studies. Never-
theless, it is noteworthy that the recom-
mendations made in the Canadian
document cited by Stein and Hunter also
clearly support the notion of graded physi-
cal exercise: “Patients should gently and
gradually increase their level of activity.”
Thus, rather than leave the severelyMJA • Volume 181 Number 10 • 15 November 2004 579
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outside their homes”, I would recommend
a carefully designed graded exercise pro-
gram in the home, with a goal of improving
functional performance sufficiently to
escape those confines.
1 Lloyd AR, Gandevia SC, Hales JP. Muscle endur-
ance, twitch properties, voluntary activation and
perceived exertion in normal subjects and patients
with chronic fatigue syndrome. Brain 1991; 114: 85-
98.
2 Royal Australasian College of Physicians Working
Group. Chronic fatigue syndrome — Clinical prac-
tice guidelines 2002. Med J Aust 2002; 176: S17-
S55. 
3 Katon W, Russo J. Chronic fatigue syndrome crite-
ria: a critique of the requirement for multiple physi-
cal complaints. Arch Intern Med 1992; 152: 1604-
1609.
4 Hadzi-Pavlovic D, Hickie IB, Wilson AJ, et al.
Screening for prolonged fatigue syndromes: valida-
tion of the SOFA scale. Soc Psychiatry Psychiatr
Epidemiol 2000; 35: 471-479. ❏
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TO THE EDITOR: While the article by
Henry and colleagues provides food for
thought and possible action,1 do they
exhibit the fairness they exhort to solve the
problem they perceive?
There appears to be a distinct lack of
logic in some of their deductions in the Box
on page 517. “Body part funding” is not
confined to Aboriginal health. For the 43
years I was associated with NSW Health, it
was an integral part of the system and,
together with its variations, increased as
the years passed.
The authors claim that as only $80 per
head being spent on medical and pharma-
ceutical benefits in a remote Aboriginal
community compared with the $900 spent
in Double Bay is an example of racism.
Surely, it is only a reflection of the lack of
both a pharmacy and doctor in the remote
community compared with the easy access
to both in the inner-Sydney suburb. Com-
parison between the remote Aboriginal
community and an all-white community of
similar characteristics would have more
validity.
1 Henry BR, Houston S, Mooney GH. Institutional
racism in Australian healthcare: a plea for decency.
Med J Aust 2004; 180: 517-520. ❏
Christopher R Strakosch
Endocrinologist, Suite 16, Greenslopes Specialist 
Centre, Newdegate Street, Greenslopes, QLD 4120. 
c.strakosch@uq.edu.au
TO THE EDITOR: In their challenging
article, Henry and coauthors assert that the
poor health of Australian Aboriginals is the
result of the “divided, divisive, racist,
socially unjust society” of “this Australia”.1
I cannot agree. The health standards
enjoyed by “white Australia” are not an
isolated phenomenon, but rather a part of
the fabric of an advanced technological soci-
ety. Efforts to bring Australian Aboriginal
health to the same standard without the
Indigenous Australians being fully part of
this 21st-century society will never be suc-
cessful, even with limitless resources and
endless goodwill.
It is possible to maintain cultural identity
and remain cognizant of past hurts while
playing a full, if not leading, role in this
technological society. 
If the Aboriginal elders were to lead their
people into mainstream society they would
find, I’m sure, an inclusive, tolerant, exciting
and advancing society where they could
play a full role, enjoy the same health as the
rest of Australia, while still maintaining their
unique identity.
1 Henry BR, Houston S, Mooney GH. Institutional
racism in Australian healthcare: a plea for decency.
Med J Aust 2004; 180: 517-520. ❏
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TO THE EDITOR: We write in response to
the article by Faunce and Bolsin on the
lessons to be drawn from three Australian
whistleblowing sagas.1 Their summary of
events at King Edward Memorial Hospital,
Perth, deserves comment.
Michael Moodie, the Chief Executive
Officer (CEO) of King Edward Memorial
Hospital, was also CEO of Princess Margaret
Hospital for Children (PMH). He was stood
down from PMH because of the concerns of
workers in response to events at PMH unre-
lated to those at King Edward Memorial
Hospital, as Faunce and Bolsin implied.
Moodie was the senior administrator
charged by the government with ensuring
that appropriate standards were in place and
were being met. Staff at PMH believed he
was unable to fulfil his brief, culminating in
votes of no confidence from the PMH Clini-
cal Staff Association, the PMH Medical Advi-
sory Committee, and a petition signed by 80
PMH doctors.
1 Faunce TA, Bolsin SNC. Three Australian whistle-
blowing sagas: lessons for internal and external
regulation. Med J Aust 2004; 181: 44-47. ❏
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IN REPLY: Our reference to Michael
Moodie as a “whistleblower” merely reiter-
ates his description as such in the report of
the Inquiry into Obstetrics and Gynaecolog-
ical Services at King Edward Memorial Hos-
pital by the Australian Council for Safety
and Quality in Health Care.1
That report states: “Both the Bristol and
King Edward case arose from ‘whistle-blow-
ers’ reporting serious problems rather than
from established safety and quality monitor-
ing systems. In Bristol’s case, the whistle-
blower was an anaesthetist and, in King
Edward’s case, it was the recently appointed
Chief Executive. In both cases, either
directly or indirectly, the department of
health received information about manage-
ment and clinical performance problems
that had not been addressed over a signifi-
cant period of time.”
The report then lists nine examples of
problems established at both institutions,
ranging from a “closed culture and environ-
ment unsupportive of openly disclosing
errors and adverse events” to “poor clinical
and emotional outcomes for patients and
families”. The report continues: “However,
there were differences in the Hospitals’
response to the inquiries. Bristol welcomed
an inquiry and actively supported the proc-
ess. In contrast, King Edward tolerated the
process and the Western Australian branch
of the Australian Medical Association
actively and publicly fought it.”
1 Australian Council for Safety and Quality in Health
Care. Lessons from the Inquiry Into Obstetrics and
Gynaecological Services at King Edward Memorial
Hospital 1990-2000. Sydney: ACSQ, 2002: 36. Avail-
able at: www.safetyandquality.org.au/articles/Publi-
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TO THE EDITOR: The complementary and
alternative medicine (CAM) series raised
awareness and provided balanced and
thoughtful debate. The article by Kerridge
and McPhee in that series1 is no exception,
but we would like to question their conclu-
sion that “not only is it unclear whether a
true integration of conventional and uncon-
ventional medicines is possible, but, more
importantly, whether it is even desirable”.
For a variety of reasons we believe that it is
both possible and desirable.
There are increasing examples of situa-
tions in which medical practitioners can
integrate ethical, evidence-based CAM into
practice. Apart from the well-known and
validated examples, such as Hypericum per-
foratum (St John’s wort) for depression, gin-
ger for nausea in pregnancy, and Gingko
biloba for intermittent claudication, there are
other, less well known, but increasingly
investigated, examples of CAM for common
conditions. With quality information and a
little training, these can be readily incorpo-
rated into medical practice.
To illustrate, Hippocrates was known to
use the herb Vitex agnus-castus (chasteberry)
for treating symptoms of premenstrual syn-
drome. Today we have a randomised con-
trolled trial (RCT) to support its use.2 There
are RCTs to support the use of Serenoa repens
(saw palmetto) for symptomatic relief of
benign prostatic hypertrophy,3 and good
evidence is accumulating for the use of
glucosamine for osteoarthritis4 and mindful-
ness meditation for preventing relapse in
recurrent depression.5
With systematic reviews on these CAMs
doctors should be informed about them.
However, the resources for promoting them
are minimal compared with those used to
promote pharmaceuticals. Considering side-
effect profiles and patient autonomy, why
shouldn’t trained medical practitioners offer
effective CAM remedies as first-line therapy
instead of a pharmaceutical? To say these
therapies should only belong to the realm of
CAM practitioners would be to deprive the
medical practitioner and patient of a wider
choice of treatments.
Communication, holism, balance and
individualised care are the hallmarks of
quality general practice and do not just
belong to CAM therapists. If orthodox med-
ical practice is to remain current, evidence-
based and relevant, general practitioners
have no option but to integrate safe, vali-
dated and ethical forms of CAM into their
practice. If they are not adequately trained
in the relevant discipline they may wish to
refer to an appropriately qualified CAM
practitioner, although statistics indicate that
GPs prefer to refer to GPs already trained in
CAM.6
1 Kerridge IH, McPhee JR. Ethical and legal issues at
the interface of complementary and conventional
medicine. Med J Aust 2004; 181: 164-166. 
2 Schellenberg R. Treatment for the premenstrual
syndrome with agnus castus fruit extract: prospec-
tive, randomised, placebo controlled study. BMJ
2001; 322: 134-137.
3 Carraro J, Raynaud J, Koch G. Comparison of phy-
totherapy (permixon) with finasteride in the treat-
ment of BPH: a randomized international study of
1,098 patients. Prostate 1996; 29: 231-240.
4 Grainger R, Cicuttini FM. Medical management of
osteoarthritis of the knee and hip joints. Med J Aust
2004; 180: 232-236. 
5 Teasdale JD, Segal ZV, Williams JM, et al. Preven-
tion of relapse/recurrence in major depression by
mindfulness-based cognitive therapy. J Consult
Clin Psychol 2000; 68: 615-623.
6 Pirotta M, Farish SJ, Kotsirilos V, Cohen MM. Char-
acteristics of Victorian general practitioners who
practise complementary therapies. Aust Fam Physi-
cian 2002; 31: 1133-1138. ❏
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TO THE EDITOR: Although Kerridge and
McPhee stress the need to find an evidence
base (if there is any) for CAM, they never-
theless claim “medical practitioners and stu-
dents no longer have any choice but to gain
some knowledge about CAM and the inter-
face between conventional and complemen-
tary medicine.”1
I suppose that archaeologists, geologists,
palaeontologists and biologists now need to
gain some knowledge about the interface
between Darwinism and Creation Science.
And our astronomers need some knowledge
about the interface between astronomy and
astrology.
Science, including effective medical care, is
not advanced by pandering to unscientific
consumerism about unproven theories, espe-
cially if it manages to get the law on its side.
Galileo was persecuted for “his heretical
view” that the earth revolved around the sun.
Have we learnt nothing from his experience?
Competing interests: Member, Australian Skeptics.
1 Kerridge IH, McPhee JR. Ethical and legal issues at
the interface of complementary and conventional
medicine. Med J Aust 2004; 181: 164-166. ❏
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IN REPLY: We agree with Kotsirilos and
Hassed that there are many examples of
successful integration of “proven” CAM into
conventional medical practice. Our ques-
tion, however, is whether it is possible to
integrate CAM where its theoretical maxims
and practices are incommensurate with allo-
pathic medicine (eg, homoeopathy) and
whether “integrative medicine” will ulti-
mately fragment and diminish CAM, further
isolate “non-evidence-based” CAM practi-
tioners and make less visible those views of
health and disease that are not consistent
with modern medicine.1
It is misleading for Arnold to imply that
there may be no evidence base for comple-
mentary and alternative medicines (CAMs).
We suggest that medical practitioners
should ask themselves not whether an “evi-
dence base” exists, but what the existing
evidence shows. The picture that emerges
from a review of the literature is one of
variable clinical efficacy. Thus, there is no
evidence to support the use of chiropractic
for childhood asthma,2 but there is good
evidence that phytomedicines may reduce
crises in sickle-cell disease,3 that cranberry
juice may reduce the frequency of sympto-
matic urinary tract infections in women,4
and that horse chestnut seed extract is an
efficacious treatment for chronic venous
insufficiency.5 There is also clinically impor-
tant evidence about harmful interactions, for
example that St John’s Wort, garlic and
ginseng may lower blood levels of warfarin.6
Medical practitioners should be critical and
sceptical of all untested claims of therapeutic
benefit. We suggest they acquaint themselves
with evidence about risks and benefits of
CAMs, particularly in their own area of prac-
tice. This is not pandering to anything. It is
evidence-based practice. By the same token,
use of CAM may reflect evidence-based deci-
sion-making by doctors and patients. It is
simply divisive to dismiss it as “unscientific
consumerism about unproven theories”, andMJA • Volume 181 Number 10 • 15 November 2004 581
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it is foolish in any case to dismiss the latter.
Medicine and science must compete with
non-scientific perspectives in the public
sphere, for the contest of ideas is never over
in human history.
Ideological positions are black and white.
Science prefers shades of grey. We have
indeed learnt much from Galileo’s experience.
1 Faass N. Integrating complementary medicine into
health systems. Gaithersburg: Aspen Publications,
2001.
2 Balon J, Aker PD, Crowther ER, et al. A comparison
of active and simulated chiropractic manipulation
as adjunctive treatment for childhood asthma. N
Engl J Med 1998; 339: 1013-1020.
3 Cordeiro N, Oniyangi O. Phytomedicines (medicines
derived from plants) for sickle cell disease. Cochrane
Database Systematic Rev 2004; 3: CD004448.
4 Jepson RG, Milhaljevic L, Craig J. Cranberries for
preventing urinary tract infections. Cochrane Data-
base Systematic Rev 2004; 1: CD001321.
5 Pittler MH, Ernst E. Horse chestnut seed extract for
chronic venous insufficiency. Cochrane Database
Systematic Rev 2004; 2: CD003230.
6 Izzo AA, Ernst E. Interactions between herbal medi-
cines and prescribed drugs. A systematic review.
Drugs 2002; 61: 2163-2175. ❏
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TO THE EDITOR: I read with interest the
article by Byles and colleagues that shows
the minimal impact of health assessments in
a section of the older Australian commu-
nity.1 While these assessments may not be
identical to the assessments covered by
Enhanced Primary Care (EPC) items on the
Medicare Benefits Schedule, my experience
performing the latter in older people leads
me to believe that they also have limited
impact.
I am now in part-time clinical practice,
with a reasonably well-defined practice pop-
ulation, comprising mostly older patients
with complex problems. My practice philos-
ophy is closer to the (perhaps old-fash-
ioned) notion of continuing, comprehensive
care, which means I have not been afraid to
spend the time needed to understand those
patients and to document their health infor-
mation. So far, I am not sure I have learned
anything new in any of the EPC health
assessments in which I have participated,
although they have been useful for initial
assessments of newer patients, as at least
they remunerate practices better for the
time-consuming task of doing this well.
However, EPC assessments may be per-
formed every 12 months. Is this really nec-
essary, unless patient circumstances change?
In my practice the answer is probably no,
although they may be more useful in prac-
tices with less stable doctor–patient relation-
ships. Would it not be a more effective use of
resources to instead allow for better-funded
initial assessments and assessments when a
patient’s condition changes, irrespective of
the timing?
1 Byles JE, Tavener R, O’Connell RL, et al. Ran-
domised controlled trial of health assessments for
older Australian veterans and war widows. Med J
Aust 2004; 181: 186-190. ❏582 MJA • Volume 181 Number 10 • 15 November 2004
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TO THE EDITOR: Telemedicine in eye care
(teleophthalmology) is one of the estab-
lished technologies in medicine, providing
the means for undertaking sophisticated eye
care and for maintaining contact with
patients in rural and remote areas.1
Telemedicine in Australia has been prima-
rily facilitated by government, against a
background of complex funding arrange-
ments and interwoven healthcare responsi-
bilities (it is funded mostly by project grants
and state government telehealth initiatives).2
This funding mechanism impedes the effi-
cient use and integration of telemedicine
services.2
The current healthcare environment
demands a detailed economic evaluation to
justify continuous funding for teleophthal-
mology. However, some of the economic
benefits of teleophthalmology may not be
directly visible in the healthcare system
itself. Significant benefit may be obtained by,
for example, savings in time and travel
expenses, thereby contributing to society
indirectly. Furthermore, the cost-effective-
ness of a telemedicine service improves con-
siderably when it is integrated with existing
routine healthcare services.3 But organisa-
tional and attitudinal barriers and lack of
funding have delayed such integration.4
These barriers relate to human resource
allocation issues in an already overstressed
healthcare system and the mindset of some
critics who view telemedicine as a peripheral
activity and a “novelty” area for technologi-
cal enthusiasts. The cost-effectiveness of
telemedicine will not be improved unless
the perception that it is an “add on” is
changed.4
The question of whether teleophthalmol-
ogy should be integrated into routine serv-
ices, with Medicare reimbursement, can be
judged by four criteria:5
• Is the technology sound? (ie, does it fulfil
its purpose?)
• Is the program effective compared with
existing care?
• Is the program cost-effective?
• Is the program practical? (ie, are there
any significant problems associated with
it?).
On the basis of our own comprehensive
evaluation of teleophthalmology in Western
Australia,6 we believe that all four questions
can be answered affirmatively, and that tele-
ophthalmology would be most efficiently
provided if integrated into existing health-
care services. Its inclusion in the Medicare
Benefits Schedule would benefit many
patients in remote and rural areas in Aus-
tralia.
1 Yogesan K, Constable IJ, Morgan B, Soebadi DY.
International transmission of tele-ophthalmology
images. J Telemed Telecare 2000; 5: 41-44.
2 Van Gool K, Haas MR, Viney R. From flying doctor to
virtual doctor: an economic perspective on Aus-
tralia’s telemedicine experience. J Telemed Tele-
care 2002; 8: 249-254.
3 Buckley D, Lower T. Factors influencing the utilisa-
tion of health services by rural men. Aust Health Rev
2002; 25(2): 11-15.
4 Mitchell J. Increasing the cost-effectiveness of tele-
medicine by embracing e-health. J Telemed Tele-
care 2000; 6(Suppl 1): S16-S19.
5 Klonoff DC. Diabetes and telemedicine: is the tech-
nology sound, effective, cost-effective and practi-
cal? Diabetes Care 2003; 26: 1626-1628.
6 Kumar SKR, Kanagasingam Y, Chaves F, et al. Tele-
medicine in eye care: cost-benefit analysis and
comparison of alternative scenarios. Arch Ophthal-
mol 2004. In press. ❏
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TO THE EDITOR: The Postcard from Hel-
ler, Weller and Jamrozik1 may reflect a
nostalgic and unrealistic view of how good
things are back home. They suggest that, in
New South Wales, the health chances of
both advantaged and disadvantaged popula-
tions are improving, and, in relative terms,
social inequalities in health may also be
showing “some improvement”.
In fact, despite impressive overall declines
in mortality, there remain important differ-
ences in health status between NSW popula-
tions. Figures for the mid-1990s show that
life expectancy at birth for both Aboriginal
males and females is markedly less (by 20
years and 18 years, respectively). Similarly,
socioeconomic disadvantage shortens life
expectancy for both rural men and women
(by 14 and 10 years, respectively) and urban
men and women (by 10 and 7 years, respec-
tively).2
The relative gap is also widening for some
important health indices. For example, from
1980 to 2000, the percentage difference in
premature death rates (< 70 years of age)
between high and low socioeconomic
groups has increased from 30% to 52% for
men and from 24% to 32% for women, and
for potentially avoidable mortality from 34%
to 63% for men and from 27% to 40% for
women.3
How should one respond to such inequal-
ities? Heller et al suggest universal rather
than targeted programs, as they are based on
sound population health principles.
To construct this as a simple choice is not
helpful. Unless we recognise and address
the barriers facing people in adverse social
circumstances, universal programs may
unintentionally widen health inequalities.
For example, universal access to healthcare
in the UK and Australia has not equally
benefited those from the most disadvan-
taged circumstances compared with wealth-
ier and better-educated populations.4
The Postcard authors suggest that Aus-
tralia is saved from class divisions by the
established “fair go” tradition, where shared
values overcome structural inequalities in
“socioeconomic status”. In fact, social class
continues to be a powerful but complex and
changing influence in Australia.5 It is impor-
tant to acknowledge the evidence that struc-
tural inequalities are significant and
worsening in Australia,6 and that the mostMJA • Volume 181 Number 10 • 15 November 2004 583
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disadvantaged experience continued social
exclusion.7
We need to shift from a “trickle down”
perspective that sees the greatest health
gains accruing to the most advantaged —
with a hope that these benefits will eventu-
ally be achieved by everyone — to a more
explicit social justice perspective that
ensures that resources for health are allo-
cated in ways that produce fair outcomes.
This may help address “socially entrenched
self-denial of the chance for better health”.
1 Heller D, Weller DP, Jamrozik K. UK health inequali-
ties: the class system is alive and well. Med J Aust
2004; 181: 128. 
2 NSW Department of Health. In all fairness: increas-
ing equity in health across NSW. Sydney: NSW
Department of Health; 2004. Available at:
www.health.nsw.gov.au/pubs/2004/pdf/fairnessre-
port.pdf (accessed Oct 2004).
3 NSW Department of Health. Public Health Division.
The health of the people of NSW: Report of the
Chief Health Officer. Sydney: NSW Health, 2002.
Available at: www.health.nsw.gov.au/public-health/
chorep/chorep.html (accessed Oct 2004).
4 Secretary of State for Health. Saving lives: our health-
ier nation. London: Stationery Office, 1999. Available
at: www.archive.official-documents.co.uk/document/
cm43/4386/4386.htm (accessed Oct 2004).
5 Greig AW, Lewins FW, White K. Inequality in Aus-
tralia. New York: Cambridge University Press, 2003.
6 Harding A. Growing apart: further analysis of
income trends in the 1990s. New South Wales
Public Health Bulletin 2002; 13(3): 51-53.
7 Peel M. The lowest rung: voices of Australian pov-
erty. Cambridge and New York: Cambridge Univer-
sity Press; 2003. ❏
Drugs, sport and the Olympics 
2000-2004
Anthony P Millar
Director of Research, Lewisham Sports Medicine 
Clinic, 1 West Street, Petersham, NSW 2049. 
tmillar@itlite.com.au
TO THE EDITOR: Pseudoephedrine is no
longer a banned substance in sport.1 It was
originally banned to protect athletes from
overuse and its dangers. Has it become
harmless or are athletes more intelligent?
This highlights much of the confusion in
drug testing. Athletes with diabetes are per-
mitted to use insulin for therapy, but those
with hypertension are not allowed to take β-
blockers. Both drugs are popularly believed
in athletic circles to improve performance.
What is to stop an athlete with diabetes from
taking extra insulin for performance
enhancement? Why do we discriminate
against those with hypertension?
There is a ban on oxygen-transport drugs
and on physical environment enhancers
such as hypobaric chambers. Both are
alleged to produce the same result, but only
use of the drug can be tested. The penalty
for the drug user is disqualification, but for
the hypobaric enthusiast a rousing cheer for
a drug-free effort. The crime is the same, so
why vary the penalty?
There is never likely to be a level playing
field under the present system, in which one
reads of positive test results being swept
under the table. How will drug testing elim-
inate the genetic inequalities between ath-
letes? How will testing improve the
availability of top-level coaches and training
facilities to all? How can it eliminate the
inequality in financial incentives, allowing
some athletes to train for 6 hours daily while
others have to work to enable them to train
for even 2 hours daily? We have swimming
costumes that decrease drag in the water,1
resulting in faster times. These are not uni-
versally available, giving their owners an
advantage. A level playing field will never
exist in our present system. It is incongru-
ous that in all this mess, only drugs are
available to all.
The current frenzy to test blood has ethi-
cal problems which have not been
addressed.2 What is to happen to an athlete
who develops an infection from a dirty
needle? Who is responsible for the tester
who has a needlestick injury from an HIV-
positive athlete? It is worth remembering
that this diagnosis will only be made 3
months after the Games, when everyone has
dispersed.
The whole area needs to be reviewed by
an outside body with no vested interest in
the outcome.
1 World Anti-Doping Agency. Code and standards.
Available at: www.wada-ama.org (accessed Aug
2004).
2 Browne A, Lachance V, Pipe A. The ethics of blood
testing as an element of doping control in sport.
Med Sci Sports Exerc 1999; 31: 497-501 ❏
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